Ombowstring,
Were trial patients dosed in that fashion (four total, initial IV- thanks FDA!) and were there equal distribution by age (fully responsibility of Cytodyn/Amarex), I believe the results would have been unequivocally positive.
My observation only, but moot now.
The investor presentation posted 4/20 indicates an additional phase 3 critical Covid trial. I expect EUA, but of course only my opinion.
Even with EUA, additional trial needed for full approval.
Incremental but inexorable progress.